Cardioversion of Atrial Fibrillation in ENGAGE AF-TIMI 48

Clin Cardiol. 2016 Jun;39(6):345-6. doi: 10.1002/clc.22537. Epub 2016 Mar 30.
No abstract available

Publication types

  • Clinical Trial, Phase III
  • Multicenter Study
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Anticoagulants / adverse effects
  • Anticoagulants / therapeutic use*
  • Atrial Fibrillation / complications
  • Atrial Fibrillation / diagnosis
  • Atrial Fibrillation / therapy*
  • Atrial Flutter / complications
  • Atrial Flutter / diagnosis
  • Atrial Flutter / therapy*
  • Combined Modality Therapy
  • Double-Blind Method
  • Electric Countershock* / adverse effects
  • Factor Xa Inhibitors / adverse effects
  • Factor Xa Inhibitors / therapeutic use*
  • Female
  • Hemorrhage / chemically induced
  • Humans
  • International Normalized Ratio
  • Male
  • Pyridines / adverse effects
  • Pyridines / therapeutic use*
  • Risk Factors
  • Stroke / diagnosis
  • Stroke / etiology
  • Stroke / prevention & control*
  • Thiazoles / adverse effects
  • Thiazoles / therapeutic use*
  • Time Factors
  • Treatment Outcome
  • Warfarin / adverse effects
  • Warfarin / therapeutic use*

Substances

  • Anticoagulants
  • Factor Xa Inhibitors
  • Pyridines
  • Thiazoles
  • Warfarin
  • edoxaban